Skip to content

Impact of Corpus Luteum Presence or Absence in the Incidence of Preeclampsia After Frozen Embryo Transfer

Impact of Corpus Luteum Presence or Absence in the Incidence of Preeclampsia After Frozen Embryo Transfer

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04092829
Acronym
PREECLAM-2019
Enrollment
591
Registered
2019-09-17
Start date
2019-09-16
Completion date
2022-12-31
Last updated
2024-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frozen Embryo Transfer, Pre-Eclampsia

Keywords

Pre-Eclampsia, Corpus Luteum, Frozen embryo transfer, Endometrial preparation

Brief summary

Identifying modifiable factors that contribute to preeclampsia risk associated with assisted reproduction can improve maternal health. Recent studies have shown an increased risk for hypertensive disorders of pregnancy after in vitro fertilization, particularly for pregnancies occurring during a hormone replacement therapy such a donor egg recipient and a frozen embryo transfer. This risk may be partly attributable to the degree by which the assisted reproductive treatment affects the maternal hormonal environment, when the corpus luteum is a major source of reproductive hormones. On the other hand, cryopreserved embryos are usually thawed and replaced in in a natural or hormonally manipulated cycle; on this point, frozen embryo transfer is associated with better perinatal outcome regarding preterm birth and low birth weight yet higher risk of large for gestational age and macrosomia compared to fresh transfer. The objective of our study is to investigate whether the absence of corpus luteum adversely affects pregnancy and to analyse if there are differences in the perinatal outcomes due to differences in the endometrial preparation protocol for a frozen embryo transfer.

Interventions

PROCEDUREFROZEN EMBRYO TRANSFER IN SUBSTITUTED CYCLE

The intervention group will be prepared with hormone replacement therapy with estrogens according to usual clinical practice. Frozen embryos will be transferred after ten doses of exogenous progesterone.

Sponsors

IVI Bilbao
CollaboratorOTHER
IVI Barcelona
CollaboratorOTHER
IVI Madrid
CollaboratorOTHER
Vida Recoletas Sevilla
CollaboratorOTHER
IVI Vigo
CollaboratorOTHER
IVI Roma
CollaboratorOTHER
Hospital Universitario La Paz
CollaboratorOTHER
IVI Mallorca
CollaboratorNETWORK
Instituto Valenciano de Infertilidad, IVI VALENCIA
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Randomized prospective analysis.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 44 Years
Healthy volunteers
No

Inclusion criteria

* All patients who, after IVF-PGT-A treatment with their own oocytes, present a euploid embryo for transfer. * Transfer of a single euploid embryo

Exclusion criteria

* Moderate or high smoking (\> 5 cigarettes/day) * BMI ≥30 kg/m2 * Chronic hypertension * History of preeclampsia in previous pregnancies * History of delayed uterine growth and placental insufficiency in previous pregnancies * Use of donor sperm * Woman's age ≥44 years * Women with menstrual cycles longer than 35 days

Design outcomes

Primary

MeasureTime frameDescription
Incidence of pre-eclampsia during pregnancy.12 monthsPresence or absence of pre-eclampsia during pregnancy

Secondary

MeasureTime frameDescription
Hypertension during pregnancy12 monthsPresence or absence of Hypertension during pregnancy
Eclampsia during pregnancy12 monthsPresence or absence of Eclampsia during pregnancy
Preeclampsia during pregnancy12 monthsPresence or absence of Preeclampsia during pregnancy
Retarded intrauterine growth during pregnancy12 monthsPresence or absence of retarded intrauterine growth at birth
Premature detachment of normoinserted placenta during pregnancy12 monthsPresence or absence of premature detachment of normoinserted placenta during pregnancy
Bleeding during pregnancy12 monthsPresence or absence of Bleeding during pregnancy
Help Sindrome during pregnancy12 monthsPresence or absence of Help Sindrome during pregnancy
Alterations in the volume of the amniotic fluid during pregnancy12 monthsPresence or absence of alterations in the volume of the amniotic fluid during pregnancy
Preterm premature rupture of membranes during pregnancy.12 monthsPresence or absence of preterm premature rupture of membranes during pregnancy
Fetal death12 monthsPresence or absence of fetal death at birth.
Type II Diabetes during pregnancy12 monthsPresence or absence of Type II Diabetes during pregnancy

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026